skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: New therapeutic modalities of retinal laser injury. Final report, 1 Mar 89-1 Mar 92

Technical Report ·
OSTI ID:7174039

Efficacies of three different regimens of high dose of methylprednisolone (MP) treatment on laser-induced non-hemorrhage retinal injury and tissue plasminogen activator (t-PA) in sub-retinal hemorrhage laser injury were evaluated in a sub-human primate model and a rat model respectively. Clinical, histopathological, and morphometric criteria were employed for evaluating the efficacy of MP. High dose and prolonged treatment (4 days) was the most effective regimen while high dose for 8 hours showed limited effect in non-hemorrhagic retinal injury. Intravitreal t-PA showed no apparent beneficial effect in sub-retinal hemorrhage after laser injury. Hence, patients with laser retinal injury may benefit from high dose MP treatment for an appropriate period of time.

Research Organization:
Illinois Univ., Chicago, IL (United States). Dept. of Ophthalmology
OSTI ID:
7174039
Report Number(s):
AD-A-251871/0/XAB; CNN: DAMD17-89-Z-9025
Country of Publication:
United States
Language:
English